scholarly journals High concordance of 70‐gene recurrence risk signature and 80‐gene molecular subtyping signature between core needle biopsy and surgical resection specimens in early‐stage breast cancer

2021 ◽  
Author(s):  
Jennifer A. Crozier ◽  
Julie Barone ◽  
Pat Whitworth ◽  
Abraham Cheong ◽  
Robert Maganini ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Surgical Resection ◽  
Core Needle Biopsy ◽  
Needle Biopsy ◽  
Early Stage ◽  
Recurrence Risk ◽  
Early Stage Breast Cancer ◽  
Molecular Subtyping ◽  
Core Needle ◽  
High Concordance

scholarly journals High concordance of 70-gene recurrence risk signature and 80-gene molecular subtyping signature between core needle biopsy and surgical resection specimen in early-stage breast cancer

2021 ◽  
Author(s):  
Jennifer A Crozier ◽  
Julie Barone ◽  
Pat Whitworth ◽  
Abraham Cheong ◽  
Robert Maganini ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Strong Correlation ◽  
Early Stage ◽  
Recurrence Risk ◽  
Gene Signature ◽  
Early Stage Breast Cancer ◽  
Molecular Subtyping ◽  
Core Needle ◽  
High Concordance ◽  
Good Concordance

Introduction: With an increase in neoadjuvant therapy recommendations for most early-stage breast cancer patients due to the COVID-19 pandemic, it has become increasingly imperative to ensure that molecular diagnostic assays provide reliable results from preoperative core needle biopsies. Therefore, the objective of this study was to determine the concordance of MammaPrint results (70-gene signature) and BluePrint results (80-gene signature) between core needle biopsies (CNB) and surgical resection (SR) specimens using prospectively collected matched tissues from patients enrolled in the FLEX trial (NCT03053193). Methods: We analyzed 113 matched CNB and SR tumor specimens from women with early-stage breast cancer enrolled in the FLEX trial. Each patient enrolled in the trial receives a MammaPrint recurrence risk classification test with or without BluePrint molecular subtyping. Concordance of MammaPrint is reported using overall percentage agreement, positive predictive value (PPV, High Risk), negative predictive value (NPV, Low Risk), and Cohens kappa coefficient. Additionally, correlations between sample types are reported using Pearson correlation coefficient. Results: We found good concordance for MammaPrint results between CNB and SR tumor samples (90.3%, k = 0.803), with a 95.1% NPV and 84.6% PPV. There was also a strong correlation of MammaPrint indices between CNB and SR specimens (r = 0.94). In addition to our primary objective, we determined the concordance of BluePrint subtyping in the matched tumor samples, and found excellent concordance (98.2%) and strong correlation of BluePrint scores within each subtype. Conclusion: CNB samples demonstrated overall high concordance with paired SR samples for MammaPrint risk classification, ensuring that physicians are provided with accurate prognostic information for therapy decisions based on testing of core biopsy tissue. Further, BluePrint molecular subtyping also had good concordance between the sample types, outperforming concordance rates based on traditional IHC based classification. Overall, with an increase in neoadjuvant therapy, physicans and patients can be assured that MammaPrint and BluePrint provide reliable results that guide timely and appropriate therapies using preoperative CNB specimens.

scholarly journals Synchronous early‑stage breast cancer and axillary follicular lymphoma diagnosed by core needle biopsy: A case report

2021 ◽  
Vol 16 (1) ◽  
Author(s):  
Ryotaro Eto ◽  
Rikiya Nakamura ◽  
Naohito Yamamoto ◽  
Toshiko Miyaki ◽  
Shoko Hayama ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Case Report ◽  
Follicular Lymphoma ◽  
Core Needle Biopsy ◽  
Needle Biopsy ◽  
Early Stage ◽  
Early Stage Breast Cancer ◽  
Core Needle

scholarly journals Factors influencing agreement of breast cancer luminal molecular subtype by Ki67 labeling index between core needle biopsy and surgical resection specimens

2020 ◽  
Vol 477 (4) ◽  
pp. 545-555
Author(s):  
Kristina A. Tendl-Schulz ◽  
Fabian Rössler ◽  
Philipp Wimmer ◽  
Ulrike M. Heber ◽  
Martina Mittlböck ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Surgical Resection ◽  
Core Needle Biopsy ◽  
Needle Biopsy ◽  
Molecular Subtype ◽  
Labeling Index ◽  
Reliable Determination ◽  
Core Needle ◽  
Luminal B ◽  
Ki67 Labeling Index

Abstract Reliable determination of Ki67 labeling index (Ki67-LI) on core needle biopsy (CNB) is essential for determining breast cancer molecular subtype for therapy planning. However, studies on agreement between molecular subtype and Ki67-LI between CNB and surgical resection (SR) specimens are conflicting. The present study analyzed the influence of clinicopathological and sampling-associated factors on agreement. Molecular subtype was determined visually by Ki67-LI in 484 pairs of CNB and SR specimens of invasive estrogen receptor (ER)–positive, human epidermal growth factor (HER2)–negative breast cancer. Luminal B disease was defined by Ki67-LI > 20% in SR. Correlation of molecular subtype agreement with age, menopausal status, CNB method, Breast Imaging Reporting and Data System imaging category, time between biopsies, type of surgery, and pathological tumor parameters was analyzed. Recurrence-free survival (RFS) and overall survival (OS) were analyzed using the Kaplan–Meier method. CNB had a sensitivity of 77.95% and a specificity of 80.97% for identifying luminal B tumors in CNB, compared with the final molecular subtype determination after surgery. The correlation of Ki67-LI between CNB and SR was moderate (ROC-AUC 0.8333). Specificity and sensitivity for CNB to correctly define molecular subtype of tumors according to SR were significantly associated with tumor grade, immunohistochemical progesterone receptor (PR) and p53 expression (p < 0.05). Agreement of molecular subtype did not significantly impact RFS and OS (p = 0.22 for both). The identified factors likely mirror intratumoral heterogeneity that might compromise obtaining a representative CNB. Our results challenge the robustness of a single CNB-driven measurement of Ki67-LI to identify luminal B breast cancer of low (G1) or intermediate (G2) grade.

scholarly journals Comparing MammaPrint and BluePrint results between core needle biopsy and surgical resection breast cancer specimens

The Breast ◽  
2021 ◽  
Vol 56 ◽  
pp. S61-S62
Author(s):  
M. Kleijn ◽  
J. McKelley ◽  
J. Wei ◽  
B. Hoxeng ◽  
A. Menicucci ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Surgical Resection ◽  
Core Needle Biopsy ◽  
Needle Biopsy ◽  
Core Needle

scholarly journals Concordance of immunohistochemistry between core needle biopsy and surgical resection of breast cancer

2017 ◽  
Vol 47 ◽  
pp. 1791-1796 ◽  
Author(s):  
Faruk Erdem KOMBAK ◽  
Hülya ŞAHİN ◽  
Hande MOLLAMEMİŞOĞLU ◽  
İdris ÖNEM ◽  
Handan KAYA ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Surgical Resection ◽  
Core Needle Biopsy ◽  
Needle Biopsy ◽  
Core Needle

The Effect of Excisional Biopsy on the Accuracy of Sentinel Lymph Node Mapping in Early Stage Breast Cancer: Comparison with Core Needle Biopsy

2010 ◽  
Vol 76 (11) ◽  
pp. 1232-1235 ◽  
Author(s):  
Mohammad Naser Forghani ◽  
Bahram Memar ◽  
Ali Jangjoo ◽  
Rasoul Zakavi ◽  
Mostafa Mehrabibahar ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Sentinel Node ◽  
Core Needle Biopsy ◽  
Needle Biopsy ◽  
Early Stage ◽  
False Negative ◽  
False Negative Rate ◽  
Excisional Biopsy ◽  
Core Needle ◽  
History Of

Despite the successful application of sentinel node mapping in breast cancer patients, its use in patients with a history of previous excisional biopsy of the breast tumors is a matter of controversy. In the present study we evaluated the accuracy of sentinel node biopsy in this group of patients and compared the results with those in whom the diagnosis of breast cancer was established by core needle biopsy. Eighty patients with early stage breast carcinoma were included into our study. Forty patients had a history of previous excisional biopsy and the remainder 40 had undergone core needle biopsy. Intradermal injections of 99mTc-antimony sulfide colloid as well as patent blue were both used for sentinel node mapping. Sentinel nodes were harvested during surgery with the aid of surgical gamma probe. All patients underwent standard axillary lymph node dissection subsequently. Detection rate was 97.5 per cent for both groups of the study. Number of detected sentinel node during surgery was not significantly different between groups. False negative rate was 0 per cent for both groups of the study. In conclusion sentinel node biopsy is reliable in patients with previous history of excisional biopsy of the breast tumors and has a low false negative rate.

Sign in / Sign up

Export Citation Format

Share Document